anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As a contribution to the field of Integral Medicine, Meditation Based Lifestyle Modification (MBLM) is a holistic therapy for patients with mental disorders. Influenced by Ayurveda and Yoga, it uses mantra meditation, ethical conduct and healthy life style to promote physical, mental and spiritual health. MBLM explains processes within the body and the mind and their relation to diet, exercise, biorhythms, social and personal conduct in an easy but profound way and on an experiential level. Besides providing tools for physical, mental and emotional self-regulation, MBLM lays ground for personal growth and transcendence of the mind. It is intended to be implemented in groups of patients as well as individual daily training, and because of its modular structure can be adjusted in intensity, duration and weighting of the components according to the specific needs and disorders to be addressed. This makes it also eligible for its potential use in prevention of mental disease and treatment of psychic comorbidities in patients with chronic somatic illness.
This study aims to evaluate if there is a difference between 180 degree nasal and temporal selective laser trabeculoplasty (SLT) in treatment outcomes. It is known that there is increased aqueous collectors and veins and thus aqueous drainage in the nasal quadrants of the eye. If SLT works by the hypothesized biologic mechanism in which macrophages remodel the aqueous drainage system to increase outflow, performing SLT in an area concentrated with aqueous veins may increase outflow more. As a result, we hypothesize that nasal 180 degree SLT may have better outcomes compared to the temporal counterpart. The results of this study may help inform decisions when performing 180 degree SLT and provide insight to SLT's mechanism of action. The primary objective of this study is to determine if there is a difference in treatment efficacy between nasal and temporal 180 degree SLT by measuring differences in baseline and post-operative intraocular pressures. We hypothesize that nasal SLT will have superior outcomes compared to temporal SLT due to increased number of aqueous veins.
PURPOSE:To provide a food or drink having excellent effect to supply nitrient in the case of the consumption of physical power after physical exercise, by using fructose or glycerol in combination with an amino acid having insulin- secretion promoting activity as active components. CONSTITUTION:The objective nutrient-supplying food or drink contains (A) fructose or glycerol and (B) one or more amino acids having insulin-secretion promoting activity (e.g. arginine, lysine, leucine, etc.). The weight ratio of B/A is (0.02-2)/1, preferably (0.15-1)/1. The amino acid is especially preferably arginine or lysine. It has various effects such as the action to maintain stamina in exercise and the action to produce glycogen in muscle and liver. There is no adverse effect to lipid metabolism even by taking the food during exercise. It is effective also to prevent obesity.
PURPOSE:To provide the title composition having pleasant taste and high foamability, containing a lactose fatty acid ester. CONSTITUTION:A composition for oral cavity application such as tooth paste, tooth powder, etc., containing 0.1-5wt%, pref. 0.3-3wt% of lactose fatty acid ester having an average esterification degree of 0.5-3.0, pref. 0.8-2.0, and containing >=60wt% of monoester. It has better taste, lower bitter and astringent taste, and higher foamability than sucrose fatty acid ester. An ionic effective component such as disinfectant, enzyme, etc. can be stably added in the composition.
PURPOSE:To obtain a thrombosis inhibitor having excellent safety, containing a 1, 2-dihydroxy-4-(2-hydroxyethyl)benzene derivative. CONSTITUTION:This thrombosis inhibitor contains a compound of formula I (R1 to R3 are H or acyl; R4 and R5 are H or short chain alkyl; R6 is H or short chain alkyloxy; Rham is rhamnose residue of formula II) and/or its salt as an active ingredient. The thrombosis inhibitor shows high blood platelet control ratio, excellent inhibitory effect on thrombosis and is effective for preventing and treating thrombosis. One or more of the thrombosis inhibitors are mixed to give a composition of medicine, food, etc. The mixed amount of the thrombosis inhibitor for a daily intake per adult is 1-1,000mg/kg calculated as the amount of the thrombosis inhibitor. The compound of formula I is obtained by extracting the whole plant of Stachys riederi of labiate plant with a solvent, filtering and purifying.
TENS SNS therapy is performed as follows; patient is asked to sit with legs slightly bent and an adhesive electrode is attached transcutaneously 5cm cephalic to either the right or left medial malleolus (subject choice). A surface electrode is placed on the medial surface of the ipsilateral calcaneum and both electrodes are connected to a low voltage electronic stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 \& w/ CVC 150mg on Day 9.
Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
<P>PROBLEM TO BE SOLVED: To provide a method for delivering exogenous antigens to a cytosol, a new fusion protein and a use of the protein.  <P>SOLUTION: The problem is solved by binding a target antigen to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen, thereby transporting the exogenous protein to the cytosol. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it is desirable to elicit a CMI response, including viral antigens and tumor antigens.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The coadministration of pimozide and OMECLAMOX-PAK may increase the pimozide plasma concentrations due to an interaction with the clarithromycin component of OMECLAMOX-PAK. Post-marketing reports indicate that coadministration of clarithromycin with pimozide has been associated with cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes). Two sudden deaths have been reported when clarithromycin was added to ongoing pimozide therapy. Pimozide is metabolized partly by CYP3A4. When clarithromycin and pimozide are administered together, inhibition of CYP3A4 by clarithromycin may lead to increased plasma exposure to pimozide. OMECLAMOX-PAK is contraindicated in patients receiving pimozide [see Contraindications (4.2)].
Despite being exposed to a high level of potentially traumatic experiences due to exposure to combat, military veterans have poor response rates to traditional PTSD treatments. In recent years 3,4-methylenedioxymethamphetamine (MDMA) has demonstrated a significant treatment potential for severe and treatment resistant PTSD though not specifically in a veteran population. The current study proposes to address the major gaps in the theoretical literature by examining the proposed mechanisms by which MDMA Assisted Therapy (MDMA-AT) enhances the "window of tolerance" for PTSD therapy, specifically in those with comorbid symptoms of moral injury; namely by reducing hyperarousal and enhancing connection (to self and others) and whether MDMA-AT is more successful in reducing PTSD in veterans compared to a matched somatic experiential PTSD treatment (SEA-IT). Sixty male veterans suffering from military-related PTSD, who have participated in at least one attempt at treatment previously, will be randomly assigned (non-blinded) to receive MDMA-AT or somatic-based therapy. All participants will undergo 3 preparation sessions and then three long (8hour) sessions each followed by 3 integration sessions. Hyperarousal will be studied using EEG (electroencephalogram) to detect significant changes in event-related neural responses and cortisol responsivity to treatment. Additionally measures of PTSD symptoms of hyperarousal and a specific measure of emotion regulation abilities will be studied. Connection will be studied as both mediated by oxytocin responsivity to treatment and as subjective outcome measures of treatment response namely using psychological measures of connection to others and self via interoceptive sensitivity. It is predicted that by using longitudinal modeling and specifically the analysis of mediators of treatment response, the current study will enable both the understanding of the promising effects of MDMA treatment and the refinement of the key contribution of MDMA-AT compared to an intensive, similarly somatic, and experimentally based, non-MDMA treatment.
PURPOSE:To obtain an anti-inflammatory and antiallergic agent containing a polyacetylenic compound as an active ingredient. CONSTITUTION:The objective substance is obtained by including a compound, e.g. 2-[(1E, 7E)-1,7-nonadiene-3,5-diynyl]furan expressed by the formula (R is H, OH or acetoxyl) as an active ingredient, further suitably blending other normally used pharmaceutical ingredients with the active ingredient and preparing a pharmaceutical according to a conventional method. The above-mentioned substance can be prepared into the form of an oral agent such as tablet, capsule, granule, fine granule or powder or a parenteral agent such as injection or suppository. The dose for an adult per day expressed in terms of the weight of the compound expressed by the formula is 50mg to 5g in the case of oral administration and 0.1mg to 1g in the case of parenteral administration. The compound expressed by the formula is obtained by extracting a herb medicine Atractylodis Rhizoma with a solvent (e.g. hexane) and then subjecting the resultant extract to chromatography.
Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
PROBLEM TO BE SOLVED: To use antithrombin III capable of reducing or at least suppressing the migration of leukocyte or the like at the time of stimulation or induction by a chemokine, e.g. interleukin-8, for the therapy of disease, especially neoplastic disease, the disease accompanied with vascularization, etc. SOLUTION: Antithrombin III is used for prophylaxis and therapy of a disease, especially a disease accompanied with neoplastic disease and vasularization, immune complex-inducing disease (e.g. vasculitis and granulomatous disease), autosmmune disease (e.g. systemic lupus erythematodes, chronic rheumatism and pemphigus), virus infectious disease (e.g. HIV), fibrotic and granulomatous disease, allergic disease (e.g. bronchial asthma, rhinitis, conjunctivitis and dermatitis), degenerative disease of nervous system (Alzheimer' s disease), arteriosclerosis, acute inflammatory disease and trauma. The antithrombin III obtained from plasma or by expressing a recombinant or transduced gene is preferably used.
The present invention relates to a series of novel taurine functional silicone polymers, useful in softening hair, and fiber and conditioning skin. Since the compounds of the present invention are high molecular weight silicone polymers, they have a high degree of oxidative stability, even at elevated temperatures. The compounds of the present invention are prepared by the reaction of chloro silicone intermediate with a taurine derivative. In a preferred embodiment the hydroxy containing silicone polymer has been alkoxylated with ethylene oxide, propylene oxide or mixtures thereof. The ability regulate the type of alkylene oxide and amount present in the silicone polymer results in a series of products ranging in water/oil solubility. The technology used to produce the compounds of the present invention is very flexible and allows us to prepare performance tailored molecules for specific applications.
A process for the treating of and/or removal of substances from a liquid, especially whole blood, via a semipermeable microporous membrane (13, 14, 15) through adsorption and/or biological reaction by means of a biologically active material. Said whole blood is exposed to pressure variations at the membrane surface in a way such that a penetrating fraction of said whole blood is flowing in an alternating flow path through the membrane walls for contacting said biologically active material. Said biologically active material is asymmetrically immobilized in and on the surface of the side of said membrane that faces away from said whole blood. Alternatively, said biologically active material may be bound to an unsoluble matrix behind said membrane. Said membrane is for example provided within a casing (7, 8, 9) comprising inlet (10) and outlet (11) for said whole blood. The space between said casing and said membrane is via a connecting nipple (12) in communication with for example an expansion chamber for the provision of pressure variations. By means of the device (3) it is possible to perform said process in one and the same step and by means of one and the same pumping system. Example of suitable materials for said membrane are regenerated cellulose, cellulose acetate, non-woven acrylic copolymer, polysulphone, polyether sulphone, polyacrylonitrile, polyamide and the like. The pores of said membrane are usually of the order of magnitude of 0.01 - 0.8 microns, preferably 0.15 - 0.45 microns. The choice of biologically active material is determined primarily by the type of substance that is to be removed.
The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
Substances diminishing the efficacy of COCs: Dienogest is a substrate of CYP3A4. Women who take medications that are strong CYP3A4 inducers should not choose Natazia as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of increased breakthrough bleeding and/or decreased contraceptive efficacy.

Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John’s wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. 

Multiple dose co-administration of the strong CYP3A4 inducer rifampin with estradiol valerate/dienogest tablets in healthy postmenopausal women led to a decrease in dienogest and estradiol systemic exposure at steady state. [See Clinical Pharmacology (12.3).]

Substances Increasing the Systemic Exposure of COCs (enzyme inhibitors): Concomitant administration of moderate or strong CYP3A4 inhibitors like azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem, and grapefruit increase the serum concentrations of both estradiol and dienogest.

In a multiple dose study investigating the effect of CYP3A4 inhibitors (ketoconazole and erythromycin) on Natazia, steady state estradiol and dienogest exposures were increased when co-administered with ketoconazole or erythromycin [see Clinical Pharmacology (12.3)]. 

Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors: Significant changes (increase and decrease) in plasma concentrations of estrogen and progestin have been noted in some cases of co-administration of HIV/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors. 

Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids.
The invention relates to health care wine capable of improving body immunity. The health care wine is prepared by soaking the following traditional Chinese medicines in Baijiu: 12g of prepared rhizome of rehmannia, 10g of eucommia bark, 15g of rhizoma dioscoreae, 15g of herba cistanche, 12g of fruit of Chinese wolfberry, 12g of radix angelica sinensis, 12g of radix astragali, 10g of seed of Chinese dodder, 10g of glossy privet fruit, 12g of bighead atractylodes rhizome,12g of cornus officinalis, 6g of liquorice root, 15g of cortex cinnamomi and 12g of radix aconiti carmichaeli. A preparation method comprises the following steps: grinding the traditional Chinese medicines, and soaking the ground traditional Chinese medicines in 5L of Baijiu with alcoholic strength higher than 50 degrees for 2 weeks, so that a wine preparation is prepared for taking. The wine is taken once respectively in the morning and in the evening by 20-50ml in each time. The health care wine disclosed by the invention has functions of tonifying kidney and supporting yang, filling essence and benefiting marrow, and strengthening tendons and bones. The health care wine has effects of boosting body immunity, resisting fatigue and the like.
Ischemic retinopathies including diabetic retinopathy are major causes of vision loss. Inner blood-retinal barrier (BRB) breakdown with retinal vascular hyperpermeability results in macular edema. Although dysfunction of the neurovascular unit including neurons, glia, and vascular cells is now understood to underlie this process, there is a need for fuller elucidation of the underlying events in BRB dysfunction in ischemic disease, including a systematic analysis of myeloid cells and exploration of cellular cross-talk. We used an approach for microglia depletion with the CSF-1R inhibitor PLX5622 (PLX) in the retinal ischemia-reperfusion (IR) model. Under non-IR conditions, PLX treatment successfully depleted microglia in the retina. PLX suppressed the microglial activation response following IR as well as infiltration of monocyte-derived macrophages. This occurred in association with reduction of retinal expression of chemokines including CCL2 and the inflammatory adhesion molecule ICAM-1. In addition, there was a marked suppression of retinal neuroinflammation with reduction in expression of IL-1b, IL-6, Ptgs2, TNF-a, and Angpt2, a protein that regulates BRB permeability. PLX treatment significantly suppressed inner BRB breakdown following IR, without an appreciable effect on neuronal dysfunction. A translatomic analysis of Müller glial-specific gene expression in vivo using the Ribotag approach demonstrated a strong suppression of Müller cell expression of multiple pro-inflammatory genes following PLX treatment. Co-culture studies of Müller cells and microglia demonstrated that activated microglia directly upregulates Müller cell-expression of these inflammatory genes, indicating Müller cells as a downstream effector of myeloid cells in retinal IR. Co-culture studies of these two cell types with endothelial cells demonstrated the ability of both activated microglia and Müller cells to compromise EC barrier function. Interestingly, quiescent Müller cells enhanced EC barrier function in this co-culture system. Together this demonstrates a pivotal role for myeloid cells in inner BRB breakdown in the setting of ischemia-associated disease and indicates that myeloid cells play a major role in iBRB dysregulation, through direct and indirect effects, while Müller glia participate in amplifying the neuroinflammatory effect of myeloid cells.
The present invention discloses a method for preparing specific nano vaccine for stomach cancer. Biologic nano emulsion is used as a drug transporting carrier in vivo, a specific polypeptide antigen MG7 for stomach cancer is used as an immune antigen, oligonucleotide (CpGODN) containing CpG motif is used as an immune adjuvant, and the nano vaccine encapsulated with MG7-Ag analog epitope polypeptide and CpGODN through a magnetic ultrasonic method. The nano vaccine has relatively high entrapment efficiency and stability when the nano vaccine particle diameter is from 20 to 30 nm through high performance liquid chromatography, electron microscope observation and centrifugation, etc. The vaccine can induce the mouse to generate anti-MG7-Ag specific antibodies and certain amount of specific CTL secreted IFN-gamma after a mouse is immunized. The antigen-adjuvant co-encapsulating group is better than the alone encapsulating group of single epitope antigen and other control groups. After tumour attack, the tumour volume of the mouse of the co-encapsulating vaccine immunity group is obviously smaller than the tumour volume of mouses of the control groups. The gene vaccine has huge intrinsic value for the immunotherapy research of stomach cancer and the development of specific vaccine for stomach cancer.
Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with a clomiphene-like selective estrogen receptor modulator (C-SERM) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and C-SERM. Oral transmucosal compositions will deliver testosterone and C-SERM directly into the patient's bloodstream, and provide high bioavailability of testosterone and C-SERM; therefore, the required doses are lower.
Femoston, oral, 1 each time, once a day. For 28 days of medication, every 28 days. Observation time for 3 courses.